Introduction
B cell chronic lymphocytic leukemia (B-CLL) is the most common leukemia of adults in Western countries. Although conventional chemotherapies can induce partial or complete remissions, these strategies cannot improve overall survival of the patients or cure B-CLL. 1 It seems evident that several pathophysiologic features of B-CLL cells contribute to the enigma that B-CLL is still an incurable disease. Among the most prominent characteristics of B-CLL cells are the inhibition of programmed cell death (apoptosis) 2, 3 and the arrest in G0/G1 phase of the cell cycle. The current study addressed the hypothesis that there may be a linkage between dysfunction of apoptosis and impaired cell cycle control in B-CLL cells.
Execution of apoptosis is controlled by the Bcl-2 family of proteins. Bcl-2, Bcl-x L , Mcl-1 and A1 have been identified as antagonists of apoptosis, whereas Bax, Bcl-x S , Bad and Bak were shown to have a pro-apoptotic effect. 4 The characteristic overexpression of Bcl-2 in B-CLL cells is considered to be an important event for the oncogenesis of this leukemia. Whereas most cases of follicular lymphoma overexpress Bcl-2 by t(14;18), 5 the majority of B-CLL cells do not contain this chromosomal translocation. 6 It is yet unknown what causes the increase of Bcl-2 in B-CLL cells and how the expression of other members of the Bcl-2 family are regulated in these cells. In addition, it is still a matter of dispute if individual members of the Bcl-2 family influence drug sensitivity of B-CLL cells in vitro. 7, 8 Cell cycle progression through G1 into S phase is regulated by the cyclins D and E, cyclin-dependent kinases (cdk) 2, 4, 5 and 6 and their inhibitors. 9 Among the cdk inhibitors p27
Kip1 has an important function as control of the restriction point by inhibiting the cyclin E/cdk2 complex. Evidently, cell cycle control appears to be dysregulated in B-CLL cells. These cells strongly express proteins that are important for G1 progression, ie cdk 4 and the cyclins E and D2, 10 ,11 yet, they do not progress into S phase. It is still unclear, which factors codetermine the levels of the cdk inhibitors in B-CLL cells thereby arresting them in G0/G1 phase of the cell cycle.
It seems plausible that the ability to repair DNA damage may further contribute to the chemoresistance of B-CLL cells. An important molecular complex involved in DNA repair is the DNA-dependent protein kinase (DNA-PK). DNA-PK is a serine-threonine protein kinase that is composed of a regulatory 80/70 kDa heterodimeric subunit (Ku80 and Ku70) and a catalytic subunit. Ku80 and Ku70 initiate DNA repair by targeting the catalytic subunit to double stranded DNA breaks. 12 Expression and regulation of Ku80 in B-CLL cells has not yet been determined.
Since apoptosis inhibition and cell cycle arrest are the main pathophysiologic features of B-CLL cells the question seems plausible if these key cellular events may be regulated by overlapping pathways. We investigated whether proteins modulating apoptosis (Bcl-2, Bax, Bcl-x L and Bcl-x S ), cell cycle (p27 Kip1 ) and DNA repair (Ku80) are coordinately expressed in B-CLL cells and in normal B cells. Furthermore, the in vitro chemosensitivity of B-CLL cells was correlated with the levels of these proteins.
Materials and methods

Patients, B-CLL samples and cell lines
B-CLL cells were isolated by Ficoll gradient centrifugation from the peripheral blood of B-CLL patients (n = 41) after obtaining informed consent. All studies were approved by the Ethics Committee of the Virchow Hospital of the Humboldt University. Fifteen patients had Binet stage A, 10 stage B and 16 stage C disease. Thirty of the 41 patients had received prior chemotherapy for their B-CLL disease. In seven cases current therapy consisted of daily chlorambucil (CBU) and prednisone. In all other cases the time between blood draw for the study and last chemotherapy was at least 2 weeks. Of the 30 treated patients, 23 were intermittently treated with a combination of chlorambucil (CBU) and prednisone. The remaining seven patients had received more than one of the following chemotherapeutic regimens during their disease course: CBU and prednisone; cyclophosphamide (CPM), vincristine and prednisone (COP); CPM, adriamycin (ADM), vincristine and prednisone (CHOP) and fludarabine (FLUD). Response to chemotherapeutic treatment was assessed according to the National Cancer Institute-sponsored Working Group guidelines. 13 Time to progression was measured from the time of diagnosis until the time of treatment.
Peripheral blood monocytes were depleted by plastic adhesion. Phenotype pattern and purity of the B-CLL samples were assessed by flow cytometry (FacScan; Becton Dickinson, Heidelberg, Germany). Diagnosis of B-CLL was confirmed by examining co-expression of CD5 (clone BL1a; DianovaImmunotech, Hamburg, Germany), CD19 (J4.119; DianovaImmunotech), CD23 low (9P.25; Dianova-Immunotech) and monoclonal surface immunoglobulin (sIg) kappa or lambda (G20-193 and JDC-12; Pharmingen, San Diego, CA, USA). Only samples with Ͼ90% B-CLL cells were used for further studies.
Normal B cells were isolated from the peripheral blood using Ficoll gradient centrifugation and anti-CD19-magnetic beads (Dynal AS, Oslo, Norway). Removal of magnetic beads was done with DETACHaBEADS (Dynal). Purity of the isolated B cells was Ͼ98% documented by flow cytometry. Viability of these cells was Ͼ97% determined by Trypan exclusion.
Western blot analysis and quantification of protein expression
B-CLL Cells (2 × 10 7 per sample) were washed with PBS and lysed on ice for 30 min in buffer (20 mM NaCl, 1 mM EDTA, 1% v/v Nonidet P40, 1 mM phenylmethylsulfonyl fluoride) containing aprotinin, leupeptin and pepstatin (250 ng/ml). Centrifugation at 12 000 g for 20 min at 4°C was followed by determination of protein of the supernatant using the BCA (bicinchoninic acid) protein assay (Pierce Europe, BA Oud Beijerland, The Netherlands). Equal amounts of protein were boiled for 5 min with sample buffer (12.5 mM Tris, pH 6.8, 1.5% w/v sodium dodecyl sulfate (SDS), 2.5% v/v 2-mercaptoethanol, 5% w/v glycerol). Proteins (30 g per lane) were separated by 12% SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (mini-protean II immunoblotting system, BioRad, Munich, Germany). Membranes (Amersham Life Science, Buckinghamshire, UK) were blocked overnight at 4°C with 2.5% w/v blocking reagent (Boehringer, Mannheim, Germany) in Tris-buffered saline (TBS, pH 8). Membranes were washed three times with TBS containing 0.05% v/v Tween 20 (Sigma, Munich, Germany) and twice with TBS. Incubation with primary antibody was performed for 2 h at room temperature. The following polyclonal antibodies (pAb) diluted with TBS were used: anti-Bax pAb (sc-493), anti-Bcl-2 pAb (sc-783), anti-Bcl-x S/L pAb (sc-634), anti-p27
Kip1 pAb (528), all obtained from Santa Cruz Biotechnology (San Diego, CA, USA) and anti-actin pAb (2066, Sigma). Only freshly thawed samples of identical batches were used. Specificity and relative sensitivity of each antiserum was verified using identical aliquots of the B-CLL cell line EHEB (American Type Cell Culture, Rockville, MD, USA) expressing all proteins examined (Bcl-2, Bax, Bcl-x L , Bcl-x S , p27 and Ku-80). This ensured a consistent activity of the antisera used. Mouse monoclonal antibody (mAb) against Ku80 (clone 111) was obtained from Pharmingen (San Diego, CA, USA). After washing, membranes were incubated with horseradish peroxidase conjugated secondary antibody diluted 1:5000 (anti-rabbit) or 1:2000 (anti-mouse) with TBS for 1 h at room temperature and washed again. ChemilumiLeukemia nescence detection was performed as described by the manufacturer (ECL, Amersham Life Science). To detect several proteins on identical membranes, blots were stripped for 20 min in strip-buffer (50 mM Tris, pH 6.8, 100 mM 2-mercaptoethanol, 2% w/v SDS) at 50°C, blocked and probed with pAbs as described above. Membranes were exposed to photographic film (Kodak, Rochester, NY, USA) for 10 s to 30 min. Films were scanned (studioscan II, Agfa Gevaert, Leverkusen, Germany) and protein bands were quantified (mean density × area) using the NIH-image program (version 1.59) on a Power Macintosh 7500/100 computer. In order to achieve comparable results between all samples analyzed with various immunoblots, the following procedure was performed: actin was used as reference protein to correct for even minor differences in the protein contents of the samples. A lysate of EHEB cells was analyzed in every blot in order to compare the results of different blots. Relative expression of a protein was calculated using the equation: relative protein expression = (protein sample /actin sample )/(protein EHEB /actin EHEB ).
Cell culture and quantification of chemotherapyinduced apoptosis
For in vitro culture, cells were maintained at 5% CO 2 in RPMI-1640 medium supplemented with 10% FCS, 1% glutamine and 1% penicillin/streptomycin. Sensitivity of B-CLL cells for drug-induced apoptosis was determined by incubating 6 × 10 5 cells in 1 ml culture medium in 24-well plates for 48 h at 37°C with different concentrations of cytostatic drugs. In order to induce cytotoxicity levels in vitro comparable with those induced in vivo, dosages were used that were within the range of the plasma concentration of these drugs given at standard doses: dexamethasone-21-dihydrogenphosphate (DEX, 1, 20, 50, 100 and 200 ng/ml; Ratiopharm, Ulm, Germany); the biologically active form of fludarabine, 5-fludarabine-monophosphate (FLUD) (kindly provided by Schering, Berlin, Germany) was used at 125, 500 and 1000 ng/ml; doxorubicinhydrochloride (adriamycin, ADM, 50, 100 and 400 ng/ml; Pharmacia, Erlangen, Germany); mafosfamide cyclophosphaminsalt which spontaneously hydrolyses in aqueous solution in the active form 4-hydroxy-cyclophosphamide (CPM; kindly donated by Dr J Pohl from Asta Medica, Frankfurt, Germany) was used at 1000 ng/ml; CBU (provided by Dr Andrea Johannes from Glaxo Welcome, Bad Odesloe, Germany) was used at 3000 ng/ml. As control, cells were incubated without adding cytostatic drugs.
Percentages of spontaneously occurring and drug-induced apoptotic cells were determined by labeling cells with Annexin-V-FITC 14, 15 (Bender MedSystems, Vienna, Austria) and propidium iodide (PI). Briefly, B-CLL cells were washed twice with ice cold PBS, dissolved in 500 l binding buffer (10 mM Hepes, 140 mM NaCl, 2.5 mM CaCl 2 ; pH 7.4) and incubated with 1.5 l Annexin-V-FITC and 10 l PI (20 g/ml, Bender MedSystems) for 15 min at room temperature. B-CLL cells were analyzed by flow cytometry. Necrotic cells and cellular debris was excluded by gating on forward and side scatter. Consistent with previous reports, [14] [15] [16] 
Statistical analyses
Significance of the correlation of two independent parameters (protein levels, spontaneous and drug-induced apoptosis) was determined by the Spearman test. Significance of differences of the mean was determined using the Mann-Whitney U-test. Significance of the differences in the drug-induced apoptosis of ADM and FLUD (calculated vs measured) was determined using the Wilcoxon test.
Results
Expression of proteins regulating apoptosis and cell cycle in B-CLL cells and in normal B cells
Expression levels of proteins regulating apoptosis (Bcl-2, Bax, Bcl-x L and Bcl-x S ), cell cycle (p27
Kip1
) and the 80 kDa regulatory component (Ku80) of the DNA repair enzyme DNA-PK in B-CLL cells and in normal B cells were determined using quantitative Western blot analyses. Differences in the protein loading, evidenced by the variation in actin expression, were equalized by using actin as a reference for the protein content of the samples. B-CLL cells contained varying amounts of all proteins examined (Figure 1 ). Compared to normal B cells, B-CLL cells expressed significantly higher levels of Bcl-2 (P = 0.004) and lower levels of Bax (P = 0.008) and contained detectable amounts of Bcl-x S (P Ͻ 0.0001). In contrast, normal and malignant B cells did not differ in their expression of Bcl-x L , p27 and Ku-80 ( Figure 1) .
Next, we aimed at determining whether the proteins showed a correlated expression pattern in B-CLL cells or in normal B cells. In B-CLL cells, the amounts of Bcl-2 showed a significant positive correlation with those of Bax (r = +0.88; P Ͻ 0.0001) and also correlated positively with the levels of p27 Kip1 (r = +0.72; P = 0.00016) (Figure 2a ). In addition, a significant positive correlation was found between the expression levels of Bcl-x L and Ku-80 (r = +0.83; P = 0.0003) (Figure 2b) . In contrast to B-CLL cells, normal peripheral B cells did not demonstrate a correlated expression of Bcl-2 and Bax (P = 0.26), Bcl-2 and p27 (P = 0.95), or Bcl-x L and Ku-80 (P = 0.85; data not shown).
Further, it was determined whether protein expression correlated with clinical relevant data. However, no correlation could be detected between the protein levels examined and Binet stage, response to chemotherapy or time to progression (data not shown).
B-CLL cells differ in their levels of drug-induced apoptosis
Chemotherapy-induced apoptosis of B-CLL cells in vitro was quantified by flow cytometric analysis of cells labeled with Annexin-V-FITC. This method is based on the specific binding of Annexin-V to phosphatidylserine which is expressed on the cell surface of early apoptotic cells. Several investigators have used this as a valid method to specifically detect the early phase of apoptosis in different cell types. 14, 15, 17, 18 Cells were also labeled with PI to detect cells in late phase of apoptosis. Apoptotic cells were defined as cells expressing Annexin-V (PI-positive and PI-negative). Necrotic cells were excluded by gating on forward and side scatter.
A panel of different chemotherapeutic drugs was tested for their ability to induce apoptosis of B-CLL cells in vitro. In order to initiate cytotoxicity levels in vitro that are comparable with those induced in vivo, dosages were used that were within the range of the plasma concentrations of these drugs given at standard doses (see Materials and methods). As shown in Figure 3 , B-CLL cells demonstrated high variations in their response to the different drugs indicating major differences in the drug-sensitivities of these cells. All chemotherapeutic drugs induced apoptosis in a dose-dependent manner (data not shown). Compared to all other drugs, CBU required a relatively high ID30 (Figure 3) . A significant correlation was noted between spontaneously occurring apoptosis and cell death induced by ADM (r = +0.53; P = 0.011) or by FLUD (r = +0.41; P = 0.045; data not shown), respectively. No correlation was observed between spontaneous apoptosis and cell death by DEX, CPM or CBU (data not shown).
We also investigated, whether drugs can act synergistically in their induction of apoptosis. In view of the clinical implication of using doses with lower toxicity, small dosages were tested. Measured death rates by combining ADM and FLUD at low concentrations were significantly higher than the calculated sum of apoptosis rates induced by the individual drugs alone (P Ͻ 0.0001; data not shown).
We aimed to determine the possible influence of the chemotherapeutic pre-treatment of patients on the extent of druginduced apoptosis of the B-CLL cells in vitro. As shown in Figure 3 , B-CLL cells of treated patients were significantly less sensitive to FLUD than leukemic cells of patients who had not received cytostatic therapy (P = 0.0001). In contrast, B-CLL cells of treated and untreated patients did not differ in their sensitivities to ADM, DEX, CPM and CBU (Figure 3) . Also, we examined whether the degree of spontaneous and drug-induced apoptosis of B-CLL cells correlated with the levels of proteins regulating apoptosis and cell cycle. However, no correlation could be detected between spontaneous cell death, sensitivities to FLUD, ADM, DEX, CPM or CBU and the expression levels of Bcl-2, Bax, Bcl-2:Bax ratio, Bcl-x L/S , p27 Kip1 or Ku80 (data not shown).
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Discussion
Deregulation of apoptosis inhibition, cell cycle arrest and DNA repair are the main determinants of the biology of B-CLL. This study investigated the complex expression pattern of proteins modulating apoptosis (Bcl-2, Bax, Bcl-x L and Bclx S ), cell cycle (p27 Kip1 ) and DNA repair (Ku80) in B-CLL cells and in normal B cells and the differential sensitivity of B-CLL cells to drug-induced apoptosis.
Compared to normal B cells, B-CLL cells contained higher levels of Bcl-2 and lower levels of Bax, supporting the concept that these major death regulators play a significant role in the pathophysiology of B-CLL. In contrast, Bcl-x L , p27 and Ku80 were not differentially expressed in normal and malignant B cells. These molecules thus appear to be relevant for both, normal and malignant cell cycle control and DNA repair. The finding that contrary to normal B cells, B-CLL cells contain detectable amounts of the pro-apoptotic Bcl-x S is interesting since inhibition of apoptosis appears to be a hallmark of B-CLL cells.
B-CLL cells demonstrated a positive correlation between the expression levels of Bcl-2 and Bax. This observation has not yet been reported 7, 19 and is surprising since both proteins appear to have opposite roles in influencing apoptosis. Yet, there are data supporting our findings. Also McConkey et al 20 reported coordinated expression levels of Bcl-2 and Bax in B-CLL cells that differed in their drug sensitivities. In addition, reports of a positive correlation between Bcl-2 and Bax in breast carcinoma demonstrates that this coordination may not be restricted to B-CLL only. 21, 22 How can the correlated expression of Bcl-2 and Bax in B-CLL cells be explained? Lack of this correlation in normal B cells supports the interpretation that this phenomenon may not occur under physiological conditions. In fact, data of Miyashita et al 23 demonstrate that abnormally high expression of Bcl-2 can lead to increased half life of Bax by a putative post-translational modulation. It seems possible, therefore, that the correlated expression of Bcl-2 and Bax in B-CLL cells may evolve during the aberrant overexpression of Bcl-2 in the leukemic cells.
Yet, the apparent paradox of a correlated expression of Bcl-2 and Bax may be partially resolved by the finding that, depending on the cellular system used, Bcl-2 and Bax are able to promote and inhibit cell death, respectively. 24, 25 Although this was not an issue of the current study, we cannot exclude the possibility that mutations of the bax gene may have lead to the expression of a detectable but dysfunctional protein. 26 Further studies are thus needed to help clarifying the nature of the functional interaction of Bcl-2 and Bax protein in B-CLL cells.
The present study also addressed the question whether in normal and malignant B cells modulators of cell death and cell cycle may be regulated by coordinated mechanisms. Solving this issue seems to be particularly relevant since the reasons for the prominent features of B-CLL cells, high Bcl-2 expression and cell cycle arrest, are yet unclear. The highly significant correlation of the expression levels of Bcl-2 and p27
Kip1 in B-CLL cells, but not in normal B cells, supports the hypothesis that these proteins may be regulated by overlapping pathways within the leukemic cells. This interpretation is supported by findings of Vrhovac et al 27 who demonstrated that high p27
Kip1 expression commonly correlates with increased in vitro survival of B-CLL cells. Furthermore, it has been shown that overexpressed Bcl-2 directly increases p27
Kip1 levels by inhibiting the proteosomal degradation of Kip1 thereby retarding G0/S phase transition. 28, 29 It seems plausible, therefore, that in B-CLL non-physiological Bcl-2 overexpression may influence p27 Kip1 levels. Increased p27
Kip1 also appears to be of clinical relevance since high protein levels correlate with poorer survival of patients with B-CLL 27 or with non-hematologic malignancies. 30, 31 Another feature that may contribute to the inhibition of apoptosis of B-CLL cells is the ability of these cells to repair DNA strand breaks. Investigating whether proteins modulating apoptosis and DNA repair may be expressed coordinately may therefore provide new information about the pathophysiology of B-CLL cells. To our knowledge, the present study is the first to report that contrary to normal B cells B-CLL cells contain correlated expression levels of Bcl-x L and the 80 kDa regulatory unit of DNA-PK. Bcl-x L and Ku80 repress cell death by targeting different cellular mechanisms. Several reports indicate that Bcl-x L is even more critical for regulating the survival of normal and malignant B cells than Bcl-2. [32] [33] [34] Direct evidence that Ku80 is involved in inhibition of apoptosis comes from the observation that pre-B cells of Ku80(−/−) mutant mice show increased spontaneous and gamma-rayinduced apoptosis. 35 Furthermore, Ku70/80 was found to be expressed independently of the cell cycle in viable but not in apoptotic HL-60 cells. 36 Also, Bcl-2 was found to sustain the levels of DNA-PK by inhibiting the proteolytic cleavage of this enzymatic complex. 37 We conclude that the concordant regulation of the two anti-apoptotic proteins Bcl-x L and Ku80 may not be part of the normal B cell physiology but instead may contribute to the pathophysiology of B-CLL.
Taken together, the current results indicate that expression of two anti-apoptotic Bcl-2 family members, ie Bcl-2 and Bclx L , may be linked to proteins regulating DNA repair and cell cycle arrest. Proteins involved in promoting apoptosis, eg Bax and Bcl-x S , seem to be excluded from these processes. Further studies are needed to determine if the observed correlations are truly functional and thereby may contribute to the longevity of B-CLL cells.
The present data provide information about the mode of action of several drugs that are most commonly used for treating B-CLL. The present study demonstrated a synergistic action of ADM and FLUD. These results are consistent with prior studies showing that FLUD enhances the in vitro cytotoxicity of topoisomerase II inhibitors. 38, 39 Furthermore, the observation that spontaneous apoptosis of B-CLL cells correlated with cell death induced by FLUD and ADM is in agreement with the literature. 7 This consistency also supports the validity of our data.
Also, the present study addressed the hypothesis that cytostatic treatment of patients with B-CLL may cause in vitro detectable drug resistance. Increased drug resistance of B-CLL cells in treated patients was reported by some authors, 40, 41 whereas others did not make this observation. 8 We found reduced sensitivity to FLUD but not to DEX, CPM or ADM in patients who received prior chemotherapeutic regiments. It is tempting to speculate that in our patient cohort resistance against FLUD may be caused by mechanisms that are induced by the drug treatment of the patients. If this is true, resistance mechanism in B-CLL cells against FLUD would be different from those against other cytostatic drugs. Support for this interpretation comes from the observation that resistance of B-CLL cells against CBU but not to FLUD can be induced by IL-2. 42 Furthermore, sensitivity to FLUD is p53-dependent whereas sensitivity to DEX is not. 43 This contrasts to observations of Silber et al 40 who reported a correlated in vitro sensitivity to FLUD and to CBU.
In vitro cytotoxicity data may help to optimize cytostatic regimens. Our observation that FLUD and ADM act synergistically in vitro supports the concept of combining FLUD with ADM or with other cytotoxic drugs to treat B-CLL. 38, [44] [45] [46] Data of the current study may initiate trials using combinations of drugs with reduced dosages that exert the same effectivity as single cytostatic agents at higher doses. Finally, the finding that in vitro sensitivity to FLUD is significantly reduced in B-CLL cells of treated patients supports the view that FLUD may be more effective in patients without prior therapy. This conclusion may support the concept of clinical studies testing FLUD as a first-line treatment of B-CLL.
However, there are several caveats when comparing results of different in vitro studies and correlating them with clinical data. As of yet, determining the in vitro chemosensitivity of B-CLL cells has not been useful to predict the clinical course of the disease or the response to cytostatic treatment. 7, 8, 43, 47 Varying expression of cofactors modulating cell death of B-CLL cells in vitro may produce functionally heterogeneous cell preparations. For example, interferon-␥ and -␣, interleukin-2 and basic fibroblast growth factor have been described to modulate in vitro apoptosis of B-CLL cells. 42, [48] [49] [50] We suppose that further modifications of the cellular and cytokine composition of the assays are needed to obtain in vitro data that mirror clinical conditions. Several observations deserve further comment. Levels of Bcl-2, Bax, Bcl-2:Bax ratio, Bcl-s L and Bcl-x S did not determine in vitro chemosensitivity or spontaneous apoptosis. These results are consistent with several reports 7, 8, 43, 47 and suggest that despite being main actors in the regulation of apoptosis Bcl-2, Bax, Bcl-s L and Bcl-x S are not relevant for influencing spontaneous or drug-induced cell death of B-CLL cells. Other studies, in contrast, found that drug sensitivity was inversely correlated with the Bcl-2:Bax ratio 19, 51 and with Bcl-2 and Bax levels. 20 Also, in vitro cytotoxicity or spontaneous cell death did not correlate with levels of p27 Kip1 or Ku80. These findings lead to the interpretation that cell death in vitro is not determined by the levels of single proteins modulating apoptosis, cell cycle and DNA repair. Instead, it seems plausible that a concerted action of these or as yet unidentified proteins is necessary for inducing spontaneous or druginduced cell death.
In conclusion, our results demonstrate coordinated levels of proteins regulating apoptosis, cell cycle control and DNA repair and a differential resistance of B-CLL cells to cytostatic drugs. Further exploring the basis of the correlated expression of these proteins will help to clarify the pathogenesis of B-CLL. In addition, designing in vitro tests that mirror clinical conditions may improve risk stratified chemotherapeutic treatment of B-CLL.
